Daniel E. Benjamin, Ph.D. Email & Phone Number

New Jersey, United States

Cenoxsys is a startup biotechnology and consulting company focused on small molecule discovery for central nervous system diseases with unmet medical need. We currently have programs in Alzheimer's and other aging-related disease, and in ALS. To advance this effort, Cenoxsys is developing a cutting edge computational system to support small molecule drug.

• AlsGen was a biotechnology company focused on the discovery and development ofdrugs for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.Under my direction, AlsGen discovered and successfully.
• Responsible for the strategic scientific focus of the company. Primary responsibility for all activities focused on the discovery, and characterization of small molecules to reduce SOD1 protein levels in ALS and other.
• Established and managed key outside academic collaborations:- Collaboration 1: Proof of concept for phase 1 clinical trial of pyrimethamine in familial ALS - Weill Cornell - Collaboration 2: Proof of concept for phase.
• Periodic data presentation and updates to the Board of Directors
• Frequent presentations at domestic and international scientific conferences
• Preparation of regulatory documents (INDs) and participated in meetings with the FDA-Initiated, developed, and maintained collaborations with international thought leaders in the areas of ALS and neurology.

PA, US

Developed high throughout robotic screening approaches to study the etiology of spinal motor atrophy Developed high throughput screening assays to discover small molecules, natural products, and biologics for the treatment of spinal motor atrophy. Implemented and developed high content intracellular imaging assays to study heteronuclear ribonuclear.

Philadelphia, Pennsylvania, US

• Provided guidance, project management, and thought leadership on multiple gene-to-screen projects focused on the discovery of small-molecule pesticides (GPCRs, enzymes, and ion channels), receiving multiple awards for.
• Guided an interdisciplinary senior management team in evaluating and approving new GPCR targets.
• Optimized screening process and reduced personnel by acquiring robotics with walk-away automation capability.
• Championed new assay technologies and supported the acquisition of a new, multifunction reader.
• Initiated the first screen at FMC in the 384-well format and led the reformatting of FMC’s library into 384-well format.
• Oversaw, mentored, and trained personnel in developing, running, and automating assays and protocols.

Led a group investigating the differentiation of stem cells for the treatment of neurological disease using high-throughput robotic technology; established key academic collaborations to obtain intellectual property and other technologies.Designed a clean room robotics system for high throughput screening to identify agents to drive the differentiation of.

New Brunswick, NJ, US

• Led a group focused on the discovery of drugs for neurological and psychiatric disease.
• Initiated the beta amyloid deposition model in mice and rats for the evaluation of Abeta aggregation inhibitors. Developed behavioral and histological endpoints to determine drug efficacy
• Initiated the Johnson & Johnson programs on Parkinson’s disease and Creutzfeldt-Jakob (CJD) disease
• Established collaboration with NIH for the study of CJD
• Managed the NK-1 in vivo program that resulted in a candidate drug entering clinical development
• Contributed significantly to the NOP program that resulted in one development candidate entering proof of concept trials

• Led the discovery of new molecular targets for advancing the treatment of alcoholism, depression, and other neuropsychiatric diseases; included extensive publishing and grant funding from federal, NIH, and foundations.
• Developed drug screening technology (pluripotent mouse P19 cell line) that was successfully transferred to Johnson and Johnson’s drug discovery program.
• Mentored and trained postdoctoral fellows and undergraduate students.
• Studied stress and the regulation of the hypothalamic pituitary axis.

Neuroscience

Doctor Of Philosophy (Phd), Molecular Neuropharmacology

Postdoctoral Studies